Fuchs Endothelial Dystrophy: Morning Blur, Its Genes and the Newer Cell Treatments
Fuchs endothelial corneal dystrophy (FECD) sits behind a familiar complaint: sight that is foggy on waking and clearer by midday. A 2010 genetic study in the New England Journal of Medicine described Fuchs endothelial corneal dystrophy as a leading cause of corneal transplantation that affects 5% of people in the United States over the age of 40. The main Corneal Dystrophy page places it among the other inherited corneal diseases. This page stays with Fuchs endothelial corneal dystrophy alone and goes further: the single layer of cells that fails, the genes found so far, how the disease is measured, the drops and transplants used for it, and the cell treatments now in trials. Every figure below is taken from the abstract of the study named beside it.
Table of Contents
- The Endothelium Is One Layer of Pump Cells That Adults Do Not Replace
- Guttae and Overnight Swelling Lie Behind the Morning Blur
- Early-Onset Fuchs Dystrophy Was Traced to COL8A2
- Late-Onset Fuchs Dystrophy Is Tied Mostly to a Repeat in TCF4
- Diagnosis Rests on the Slit Lamp, Cell Counts and Thickness Maps
- Hypertonic Saline Drops Have Mixed Results
- Endothelial Transplants Replace the Failed Layer
- Descemet Stripping Only Relies on the Eye's Own Cells
- Cultured Endothelial Cells Can Be Injected Into the Eye
- Ultraviolet Light Reproduces Fuchs-Like Damage in Mice
- Much About Fuchs Dystrophy Is Still Unknown
- Key Research Papers
- Connections
- Featured Videos
The Endothelium Is One Layer of Pump Cells That Adults Do Not Replace
The cornea is the clear front window of the eye. Its inner surface is lined by the corneal endothelium, which a 2003 review by Joyce describes as the single layer of cells forming a boundary between the corneal stroma (the thick middle layer of the cornea) and the anterior chamber (the fluid-filled space behind it). The review gives this layer two jobs, a barrier and a “pump”, and states that together they keep the cornea transparent by regulating how much water the stroma holds.
The same review sets out why the layer is so hard to repair. Microscope studies show an age-related decrease in endothelial cell density, and the review concludes that the endothelium in the living eye either does not divide at all or divides at a rate that does not keep pace with the rate of cell loss. In the review's words, this lack of a strong repair response makes the endothelium “at best, a fragile tissue.”
The cells are not incapable of dividing. Work summarised in the review found them held in the G1 phase of the cell cycle, a resting stage before DNA is copied. Several brakes appear to keep them there:
- Transforming growth factor-beta, a signalling protein present in the aqueous humor (the clear fluid in the front of the eye), suppressed entry into the DNA-copying phase in cultured endothelial cells.
- Contact between neighbouring cells, partly through a cell-cycle brake called p27kip1, appears to hold the mature layer in a non-dividing state.
- The cells make growth factors and their receptors, yet appear unable to respond to them in the living eye.
In laboratory studies of wounded donor tissue, cells from donors older than 50 years could still enter and complete the cell cycle, but their resting phase was longer and they needed stronger growth signals than cells from donors younger than 30. The review links excess cell loss — from accidental or surgical injury, dystrophy or disease — to a layer that can no longer hold back fluid from the aqueous humor, with corneal swelling, loss of clarity and loss of sight that may require corneal transplantation. That chain is the one Fuchs dystrophy follows, slowly, and it explains why the treatments further down either replace the cells or try to help the remaining ones spread.
Guttae and Overnight Swelling Lie Behind the Morning Blur
The 2010 genetic study by Baratz and colleagues summarised the disease process in four steps. Clinically visible deposits called guttae develop under the corneal endothelium. Under the microscope there is a loss of endothelial cells and deposition of an abnormal extracellular matrix (the structural material cells lay down around themselves). In advanced disease the cornea swells and becomes cloudy, because the remaining endothelial cells are not sufficient to keep it dehydrated and clear.
A 2019 prospective study from Germany measured how that swelling changes across a day. Eyes with clinically advanced Fuchs dystrophy that were due for a transplant, and healthy eyes, were measured around noon and late afternoon, patched overnight to standardise eyelid closure, and measured again the moment they opened in the morning. Corneal thickness was mapped with Scheimpflug imaging, a rotating camera that photographs the cornea in cross-section.
- Directly upon awakening, the 44 Fuchs dystrophy eyes had a mean corneal thickness of 663 µm (interquartile range 625–707), against 557 µm (interquartile range 527–601) in 11 control eyes.
- Control corneas showed no systematic change over time.
- In Fuchs dystrophy eyes, thickness fell after waking: the authors expected 95% of patients to lose between 31 µm and 58 µm over the first 4 hours.
- As the swelling cleared, the back surface of the central cornea steepened.
- Beyond 4 hours after waking, the Fuchs dystrophy corneas no longer changed considerably.
The authors drew a practical conclusion about measurement: in clinically advanced Fuchs dystrophy, readings of key corneal measures taken straight after eye opening are unreliable, while readings taken beyond the first hours vary no more than in normal eyes. The randomised drop trial described in the hypertonic saline section, run by the same group with the same morning set-up, also recorded subjective visual function rising over the hours after eye opening.
Early-Onset Fuchs Dystrophy Was Traced to COL8A2
The first gene tied to any corneal endothelial dystrophy was reported in 2001 by Biswas and colleagues. They studied a three-generation family with early-onset Fuchs endothelial corneal dystrophy. A genome-wide search linked the disease to a 6–7 cM stretch of chromosome 1p34.3–p32, which contains COL8A2. This gene encodes the 703 amino acid alpha2 chain of type VIII collagen, a short collagen that is a component of endothelial basement membranes — the thin sheet that endothelial cells rest on, which in the cornea is called Descemet membrane.
The family carried a missense mutation (a single changed building block in the protein), gln455lys, within the triple helical part of the collagen. Testing other patients found further missense changes in familial and sporadic cases of Fuchs dystrophy and in a single family with posterior polymorphous corneal dystrophy, another disease of the endothelium. The authors described this as the first account of the molecular basis of any corneal endothelial dystrophy, and suggested that the disease may come from a disturbance of type VIII collagen's role in the final maturation of the endothelial cells, which arise from the neural crest during development.
The 2010 study by Baratz and colleagues noted that rare gene variants had by then been found for both the early-onset and the typical late-onset forms. Riazuddin and colleagues describe late-onset Fuchs dystrophy, the form covered next, as a common age-related disorder.
Late-Onset Fuchs Dystrophy Is Tied Mostly to a Repeat in TCF4
A genome-wide study found TCF4
Before 2010, no common gene variant had been linked to Fuchs dystrophy. That year, Baratz and colleagues ran a genome-wide association study and replicated it in a second, independent group. Variants in TCF4, the gene for transcription factor 4 (a protein also called E2-2), were associated with typical Fuchs dystrophy (P = 2.3 × 10-26). People with two copies of the disease variants had 30 times the odds of having the disease, and the variants told cases from controls with about 76% accuracy. At least two regions of the gene were independently associated.
The repeat inside TCF4
In 2012, Wieben and colleagues looked at a three-letter DNA repeat inside an intron (a non-coding stretch) of TCF4, which their paper calls a TGC repeat. They measured its length in blood DNA from 66 people with severe Fuchs dystrophy and 63 people with normal corneas:
- A repeat length above 50 was found in 52 of 66 cases (79%) and in 2 of 63 controls (3%).
- 13 cases (20%) had fewer than 40 repeats.
- In 4 cases the repeat was longer than 1,000.
- More than 50 repeats identified Fuchs dystrophy with a sensitivity of 79% and a specificity of 96%, more specific than the single-letter variant rs613872 found earlier (specificity 79%).
The authors concluded that the expansion may play a disease-causing role in the majority of cases. A 2022 study from northern Sweden reached a similar figure: an expansion above 50 repeats was present in 76 of 85 people with Fuchs dystrophy (89.4%) and in 4 of 102 controls (3.9%). The median repeat length was 81 in mild disease and 87 in severe disease (p = 0.01), and a longer expanded repeat raised the probability of severe disease. Other eye surgery was more common among cases without the expansion (44.4%, n = 4) than among cases with it (3.9%, n = 3), and the authors suggested that eye surgery might act as an environmental factor in Fuchs dystrophy without the repeat.
How the repeat might cause damage
A 2021 review by Fautsch and colleagues, which refers to the expansion as CTG18.1, states that genetic and molecular studies implicate it as a causal variant in the majority of Fuchs dystrophy patients. The review lists four proposed mechanisms, which do not exclude one another:
- Disturbed regulation of the TCF4 gene itself.
- A toxic gain of function from RNA that carries the repeat.
- A toxic gain of function from repeat-associated non-AUG translation, in which the repeat is read into abnormal proteins.
- Somatic instability, meaning the repeat changes length within the body's own cells over time.
The review states that the relative contribution of these mechanisms to the disease is currently unknown.
SLC4A11 makes a smaller contribution
Two faulty copies of SLC4A11, a gene for a borate cotransporter, cause two early-onset corneal dystrophies: congenital hereditary endothelial dystrophy and Harboyan syndrome. In 2010, Riazuddin and colleagues sequenced the gene in 192 people with sporadic late-onset Fuchs dystrophy or small families with it. They found seven new single-copy missense changes absent from ethnically matched controls; one followed a dominant pattern through a three-generation family, and laboratory tests showed the changes affected where the protein sits in the cell and how it is modified. The authors concluded that single-copy SLC4A11 mutations are modest contributors to adult Fuchs dystrophy and proposed a continuum between it and congenital hereditary endothelial dystrophy.
A related repeat disease shows mild corneal changes
In myotonic dystrophy type 1 a CTG repeat expansion lies in a different gene, DMPK. A 2025 study from Japan examined 19 eyes of 10 people with myotonic dystrophy type 1 and 72 eyes of 37 healthy people. Two patients had guttae in both eyes equal to the mildest grade of Fuchs dystrophy, and dark areas on specular microscopy appeared in 4 of 19 eyes (21.1%) against 0 of 72 control eyes. Average endothelial cell density was higher in the myotonic dystrophy group (3,536 cells/mm2) than in controls (3,026 cells/mm2). The TCF4 repeat expansion was not found in the eyes with guttae. More on the muscle disease is on the Myotonic Dystrophy page.
Diagnosis Rests on the Slit Lamp, Cell Counts and Thickness Maps
The 2024 third edition of the classification by the International Committee for the Classification of Corneal Dystrophies (IC3D) updates standard templates for 22 corneal dystrophies, each with a level of evidence from category 1 (most evidence) to category 4 (least), and adds a management table. Within Fuchs dystrophy, three kinds of examination recur across the studies on this page.
- Slit-lamp examination. Guttae are visible at the slit lamp, the eye microscope used in eye examinations. In a 2020 study by Patel and colleagues, cornea specialists graded eyes by the area and confluence (how much the spots merge) of the guttae and by whether clinically definite swelling was present.
- Specular microscopy. This photographs the endothelium so that the cells can be counted. The Japanese myotonic dystrophy study above used it to report endothelial cell density in cells per square millimetre and to find dark areas in the cell layer.
- Corneal thickness. Thickness can be measured with ultrasound (ultrasonic pachymetry), Scheimpflug imaging or anterior segment optical coherence tomography, a light-based scan of the front of the eye.
Thickness maps predicted progression better than thickness alone
Patel and colleagues followed 96 eyes of 56 people with a range of Fuchs dystrophy severity over a median of 5 years. Progression meant new clinically definite swelling, a 5% or greater increase in central corneal thickness, or an endothelial transplant. Three patterns on Scheimpflug thickness and back-surface maps were assessed: loss of regular isopachs (the even rings of equal thickness), displacement of the thinnest point of the cornea, and a focal depression of the back surface.
- Central corneal thickness on its own was not a significant risk factor (hazard ratio 1.30 per 25-µm increase, P = 0.15).
- In the combined analysis, loss of regular isopachs (hazard ratio 11.57) and displacement of the thinnest point (hazard ratio 5.61) were independent risk factors.
- The 5-year cumulative risk of progression or transplant was 7%, 48% and 89% when none, 1 or 2, or all 3 patterns were present.
- After uncomplicated cataract surgery, the 4-year cumulative risk was 0%, 50% and 75% for the same three groups.
The timing caveat from the diurnal study applies here too: in advanced disease, thickness readings taken straight after waking were unreliable.
Gene testing measures the repeat in blood
The repeat studies above measured TCF4 repeat length in DNA from blood. The Swedish study used short tandem repeat polymerase chain reaction (PCR) and triplet repeat-primed PCR; the 2012 study used direct sequencing, a short tandem repeat assay and Southern blotting for samples in which only one copy could be read.
Hypertonic Saline Drops Have Mixed Results
Hypertonic saline is salt water stronger than tears, used as drops on the theory that it draws water out of a swollen cornea. Two records point in different directions.
A review of 16 studies
A 2021 review by Chow and Chan covered 16 articles on hypertonic saline drops: 4 randomised trials, 6 prospective studies, 4 retrospective studies and 2 case reports, 5 of them in Fuchs dystrophy. Results varied widely with the disorder treated. There was limited benefit in bullous keratopathy, where the swelling involves the surface layer (epithelium) of the cornea, whereas most studies noted clinical improvement when the swelling did not involve the epithelium, especially in Fuchs dystrophy or in corneal hydrops of keratoconus. Reported side effects were a mild stinging or burning sensation, with no serious complications. The review concluded that the drops seem safe and effective in less severe corneal swelling.
A randomised trial of morning swelling
The Eye Drops for Early Morning-Associated Swelling (EDEMAS) trial, published in 2021, tested hyperosmolar drops directly against artificial tears. Its 68 participants had Fuchs dystrophy and were scheduled for a transplant; one eye was randomised to the hyperosmolar drops and the fellow eye to artificial tears, double-masked. The drops were given twice after eye opening, and the cornea was scanned every 30 minutes for up to 4 hours.
- All eyes had swelling of the stroma; none had swelling of the epithelium.
- After eye opening, corneal thickness was 626 µm in the treated eyes and 622 µm in the placebo eyes, a morning swelling of +21 µm and +24 µm over the afternoon baseline.
- One hour later thickness had fallen by 10.5 µm with the drops and 11.2 µm with placebo (difference 0.7 µm, P = 0.59).
- Results did not fit a meaningful effect on corneal thickness, visual acuity or glare over the whole study, and subjective vision improved less quickly in the treated eyes.
- Adverse events, most often burning after the drops, occurred in 30 treated eyes and 1 placebo eye.
The authors concluded that the drops did not speed the clearing of early-morning swelling of the stroma, caused more adverse events, and that the results do not support their routine use. The trial measured only the morning hours in eyes with stromal swelling; it did not test long-term daily use or eyes with epithelial swelling.
Endothelial Transplants Replace the Failed Layer
A 2018 Cochrane review states that corneal endothelial transplantation has become the gold standard for endothelial failure, replacing penetrating keratoplasty (the full-thickness corneal transplant). Two main forms are in use. Descemet stripping automated endothelial keratoplasty (DSAEK) transplants donor endothelium on a thin backing of donor stroma; in a Dutch randomised trial, its ultrathin grafts measured 101 µm at the centre. Descemet membrane endothelial keratoplasty (DMEK) transplants only the donor's Descemet membrane and endothelium.
The comparison evidence
The Cochrane review, searching up to August 2017, found no randomised trials of Descemet membrane endothelial keratoplasty against Descemet stripping automated endothelial keratoplasty. It found four non-randomised studies of 72 people (144 eyes) with Fuchs dystrophy who had the older operation in one eye and the newer one in the fellow eye.
- At one year, Descemet membrane endothelial keratoplasty may give better best-corrected vision (mean difference −0.14 logMAR, 140 eyes, low-certainty evidence; on the logMAR scale, lower numbers mean sharper sight).
- For endothelial cell counts, two studies suggested no difference and two found higher counts after Descemet membrane endothelial keratoplasty, so no conclusion could be drawn.
- There was no primary graft failure and one graft rejection across 144 eyes.
- Graft dislocation was more common after Descemet membrane endothelial keratoplasty (risk ratio 5.40, very low-certainty evidence).
A randomised trial at 6 Dutch corneal centres, published in 2020 by Dunker and colleagues, then compared the two in 54 eyes with Fuchs dystrophy that had already had cataract surgery (29 Descemet membrane endothelial keratoplasty, 25 ultrathin Descemet stripping automated endothelial keratoplasty).
- At 12 months, best spectacle-corrected vision was 0.08 logMAR after Descemet membrane endothelial keratoplasty and 0.15 logMAR after the ultrathin operation, a difference that was not statistically significant (P = 0.06).
- The share of eyes reaching 20/25 vision was higher after Descemet membrane endothelial keratoplasty (66% against 33%, P = 0.02).
- Endothelial cell density at 12 months did not differ significantly (1,870 against 1,612 cells/mm2, P = 0.12).
- Both operations produced a mild shift toward long-sightedness.
Ten years after Descemet membrane endothelial keratoplasty
A prospective study from Düsseldorf, Germany, published in 2024, included 201 eyes; 54 eyes (45 with Fuchs dystrophy, 9 with swelling after cataract surgery) reached at least 5 years of follow-up, and 37 reached 8 to 10 years. Mean follow-up was 94.4 months.
- Best-corrected vision improved from 0.6 to 0.1 logMAR at 6 months.
- Endothelial cell density fell from 2,488 cells/mm2 in the donor tissue to 980.1 cells/mm2, an average loss of 4% a year, and the loss did not correlate with vision.
- Central corneal thickness fell from 596.9 µm to 498.6 µm at 12 months and then stayed stable.
- Eight eyes (14.8%) needed at least one rebubbling, an injection of air to press a loose graft back into place.
- Primary graft failure was 1.5% and rejection 0% in the first year; secondary graft failure was 12.4% at 7 years.
- Eight eyes (14.8%) had open-angle glaucoma, 3 present before surgery and 5 new.
The authors concluded that although cell density keeps falling, excellent vision can be preserved 10 years after the operation, and that the final outcome can be estimated 6 months after surgery.
Descemet Stripping Only Relies on the Eye's Own Cells
Descemet stripping only removes the diseased central Descemet membrane and its guttae without placing any donor tissue, so the bare centre has to be covered by the patient's own remaining endothelial cells. Ripasudil is a rho-kinase inhibitor eye drop. A 2026 report by Colby, Kruse and Kinoshita gives the results of a one-year, phase 2, randomised, placebo-controlled trial at several centres, in which ripasudil was given for 12 weeks after Descemet stripping only in Fuchs endothelial corneal dystrophy, at two doses (four times daily and twice daily) against placebo. The main outcome, central endothelial cell density at 12 weeks, was read by an independent centre that did not know each person's group.
- Sixty-five people enrolled, and over 95% completed the trial.
- At 12 weeks, central endothelial cell density was 531 ± 312 cells/mm2 in the four-times-daily group against 228 ± 298 cells/mm2 with placebo (P = .0065).
- Corneal swelling had cleared at 12 weeks in 17 of 21 (81.0%) of the four-times-daily group and 2 of 22 (9.1%) of the placebo group (P < .0001).
- Rescue treatment was needed in 2 of 21 (9.5%) of the four-times-daily group and 6 of 22 (27.3%) of the placebo group (P = .0092).
- Adverse events were mild and did not lead anyone to stop treatment.
The abstract reports the four-times-daily group against placebo; it gives no separate figures for the twice-daily group. The trial ran for one year, so it does not show how the cell layer holds up over many years.
Cultured Endothelial Cells Can Be Injected Into the Eye
A different approach grows donor endothelial cells in the laboratory and injects them into the front chamber of the eye, together with a rho-associated protein kinase (ROCK) inhibitor.
The first human study, 2018
Kinoshita and colleagues, writing in the New England Journal of Medicine, named disorders of the endothelial cells such as Fuchs endothelial corneal dystrophy as causes of bullous keratopathy, the hazy, swollen cornea of endothelial failure. Their uncontrolled, single-group study involved 11 people with bullous keratopathy and no detectable endothelial cells. Cells cultured from a donor cornea, 1 × 106 in total, were mixed with a rho-associated protein kinase inhibitor (final volume 300 µl) and injected into the front chamber of one eye; patients then lay face down for 3 hours.
- At 24 weeks, all 11 treated eyes had a central cell density above 500 cells/mm2 (range 947 to 2,833), and 10 had more than 1,000.
- A corneal thickness below 630 µm (range 489 to 640) was reached in 10 of 11 eyes.
- Best-corrected vision improved by two lines or more in 9 of 11 eyes.
The ESCALÓN randomised trial, 2025
ESCALÓN was a prospective, randomised, double-masked trial of the same idea. Eyes with bullous keratopathy (18) or Fuchs dystrophy (4) had the back surface of the cornea polished and received a single injection of 1 × 106 cultured human corneal endothelial cells with one of three doses (10, 20 or 100 µM) of the rho-associated protein kinase inhibitor Y-27632. Results from the dose groups were pooled because they did not differ meaningfully.
- Twenty-two eyes were treated, with no serious adverse events in the study eyes.
- The most common adverse events were clouding of the lens capsule behind an implanted lens (posterior capsule opacification, 72.7%), pupil disorders (27.3%) and short-lived rises in eye pressure (22.7%).
- Mean central corneal thickness fell from 697.0 µm to 571.2 µm at 12 months.
- Mean best-corrected vision improved from 0.995 to 0.330 logMAR, and 88.9% of subjects gained at least 0.3 logMAR by 12 months.
- No meaningful dose response for Y-27632 was seen.
The abstract does not break out results for the 4 eyes with Fuchs dystrophy, so the trial says little about Fuchs dystrophy on its own.
Ultraviolet Light Reproduces Fuchs-Like Damage in Mice
Late-onset Fuchs dystrophy is more common in women, and a 2020 mouse study by Liu and colleagues looked for an environmental reason. In mice, aiming ultraviolet A (UVA) light at the cornea reproduced the cell and molecular changes of Fuchs dystrophy and produced reactive oxygen species in the aqueous humor.
- In mice, female animals lost more endothelial cells, more of the tight contacts between cells (ZO-1) and had more corneal swelling than male animals.
- In mice, ultraviolet A caused more damage to mitochondrial and nuclear DNA in females.
- In mice, the sex difference was driven by activation of the estrogen-processing enzyme CYP1B1 and by reactive estrogen breakdown products and estrogen-DNA adducts that formed in female but not male animals.
- In mice, N-acetylcysteine, a scavenger of reactive oxygen species, lessened the changes caused by ultraviolet A.
These are animal results. No human study testing whether ultraviolet exposure speeds Fuchs dystrophy, or whether N-acetylcysteine changes its course, was among the records read for this page. The drug itself is covered on the N-Acetylcysteine page.
Much About Fuchs Dystrophy Is Still Unknown
- How the TCF4 repeat does its damage. The 2021 review lists four candidate mechanisms and states that their relative contribution is currently unknown.
- Why the repeat does not always mean disease. A repeat above 50 turned up in 2 of 63 controls in the 2012 study and in 4 of 102 controls in the Swedish study, and a minority of patients in both studies had no expansion.
- What causes Fuchs-like changes without the repeat. The Swedish authors suggested earlier eye surgery as a possible environmental factor; the myotonic dystrophy study found guttae with no TCF4 expansion.
- Which transplant gives the better long-term result. The Cochrane review found no randomised trials and rated its evidence low or very low certainty; the later Dutch randomised trial had 54 eyes and 12 months of follow-up.
- Whether hypertonic saline helps. A review of mostly small studies was favourable for swelling without epithelial involvement; the one randomised trial of morning swelling found no effect.
- How durable Descemet stripping only with ripasudil is. The trial was phase 2, with 65 people and one year of follow-up.
- How well cell injection works in Fuchs dystrophy specifically. The first study had 11 eyes and no control group; ESCALÓN had 22 eyes, only 4 of them with Fuchs dystrophy.
- Whether ultraviolet light matters in people. The evidence read here is from mice.
Key Research Papers
- Joyce NC. Proliferative capacity of the corneal endothelium. Prog Retin Eye Res. 2003;22(3):359-89. PubMed PMID: 12852491
- Baratz KH, Tosakulwong N, Ryu E, Brown WL, Branham K, Chen W, et al. E2-2 protein and Fuchs's corneal dystrophy. N Engl J Med. 2010;363(11):1016-24. PubMed PMID: 20825314
- Fritz M, Grewing V, Maier P, Lapp T, Böhringer D, Reinhard T, Wacker K. Diurnal Variation in Corneal Edema in Fuchs Endothelial Corneal Dystrophy. Am J Ophthalmol. 2019;207:351-355. PubMed PMID: 31415734
- Biswas S, Munier FL, Yardley J, Hart-Holden N, Perveen R, Cousin P, et al. Missense mutations in COL8A2, the gene encoding the alpha2 chain of type VIII collagen, cause two forms of corneal endothelial dystrophy. Hum Mol Genet. 2001;10(21):2415-23. PubMed PMID: 11689488
- Wieben ED, Aleff RA, Tosakulwong N, Butz ML, Highsmith WE, Edwards AO, Baratz KH. A common trinucleotide repeat expansion within the transcription factor 4 (TCF4, E2-2) gene predicts Fuchs corneal dystrophy. PLoS One. 2012;7(11):e49083. PubMed PMID: 23185296
- Viberg A, Westin IM, Golovleva I, Byström B. TCF4 trinucleotide repeat expansion in Swedish cases with Fuchs' endothelial corneal dystrophy. Acta Ophthalmol. 2022;100(5):541-548. PubMed PMID: 34644448
- Fautsch MP, Wieben ED, Baratz KH, Bhattacharyya N, Sadan AN, Hafford-Tear NJ, et al. TCF4-mediated Fuchs endothelial corneal dystrophy: Insights into a common trinucleotide repeat-associated disease. Prog Retin Eye Res. 2021;81:100883. PubMed PMID: 32735996
- Riazuddin SA, Vithana EN, Seet LF, Liu Y, Al-Saif A, Koh LW, et al. Missense mutations in the sodium borate cotransporter SLC4A11 cause late-onset Fuchs corneal dystrophy. Hum Mutat. 2010;31(11):1261-8. PubMed PMID: 20848555
- Kubo K, Oie Y, Koto R, Nishida N, Kai C, Maeno S, et al. Analysis of Corneal Phenotypes in Japanese Patients With Myotonic Dystrophy Type 1. Cornea. 2025;44(4):412-417. PubMed PMID: 39167633
- Patel SV, Hodge DO, Treichel EJ, Spiegel MR, Baratz KH. Predicting the Prognosis of Fuchs Endothelial Corneal Dystrophy by Using Scheimpflug Tomography. Ophthalmology. 2020;127(3):315-323. PubMed PMID: 31685256
- Chow SC, Chan JC. Review on the Use of Topical Ocular Hypertonic Saline in Corneal Edema. Cornea. 2021;40(4):533-539. PubMed PMID: 33470681
- Zander DB, Böhringer D, Fritz M, Grewing V, Maier PC, Lapp T, et al. Hyperosmolar Eye Drops for Diurnal Corneal Edema in Fuchs' Endothelial Dystrophy: A Double-Masked, Randomized Controlled Trial. Ophthalmology. 2021;128(11):1527-1533. PubMed PMID: 33892048
- Stuart AJ, Romano V, Virgili G, Shortt AJ. Descemet's membrane endothelial keratoplasty (DMEK) versus Descemet's stripping automated endothelial keratoplasty (DSAEK) for corneal endothelial failure. Cochrane Database Syst Rev. 2018;6(6):CD012097. PubMed PMID: 29940078
- Dunker SL, Dickman MM, Wisse RPL, Nobacht S, Wijdh RHJ, Bartels MC, et al. Descemet Membrane Endothelial Keratoplasty versus Ultrathin Descemet Stripping Automated Endothelial Keratoplasty: A Multicenter Randomized Controlled Clinical Trial. Ophthalmology. 2020;127(9):1152-1159. PubMed PMID: 32386811
- Teubert S, Borgardts K, Steindor F, Borrelli M, Schrader S, Geerling G, Spaniol K. Ten-Year Follow-Up After Descemet Membrane Endothelial Keratoplasty. Cornea. 2024;44(9):1119-1126. PubMed PMID: 39476369
- Colby K, Kruse FE, Kinoshita S. Descemet Stripping Only in Fuchs Endothelial Corneal Dystrophy: Results of a Randomized Clinical Trial of Topical Ripasudil and Directions for Future Innovation. Am J Ophthalmol. 2026;290:145-160. PubMed PMID: 42303065
- Kinoshita S, Koizumi N, Ueno M, Okumura N, Imai K, Tanaka H, et al. Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy. N Engl J Med. 2018;378(11):995-1003. PubMed PMID: 29539291
- Holland EJ, Yeu E, Giegengack M, Berdahl J, Jordan E, Quesada R, et al. ESCALÓN: A Prospective Randomized Trial of Corneal Endothelial Cell Therapy in Subjects With Corneal Edema. Cornea. 2025;44(12):1497-1507. PubMed PMID: 40032264
- Liu C, Miyajima T, Melangath G, Miyai T, Vasanth S, Deshpande N, et al. Ultraviolet A light induces DNA damage and estrogen-DNA adducts in Fuchs endothelial corneal dystrophy causing females to be more affected. Proc Natl Acad Sci U S A. 2020;117(1):573-583. PubMed PMID: 31852820
- Weiss JS, Rapuano CJ, Seitz B, Busin M, Kivelä TT, Bouheraoua N, et al. IC3D Classification of Corneal Dystrophies-Edition 3. Cornea. 2024;43(4):466-527. PubMed PMID: 38359414
PubMed Topic Searches
Connections
- Corneal Dystrophy — the parent page on all the inherited corneal dystrophies
- Ophthalmology — the eye-disease section
- Keratoconus — another corneal disease; the hypertonic saline review also covered its corneal hydrops
- Cataracts — Fuchs progression after cataract surgery was measured in the thickness-map study
- Glaucoma — open-angle glaucoma was recorded in the ten-year transplant study
- Corneal Ulcer — another cause of corneal damage
- Myotonic Dystrophy — a CTG repeat disease with mild Fuchs-like corneal changes
- N-Acetylcysteine — lessened ultraviolet damage to the cornea in mice